CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation

Here, we report the response rate, toxicity, and survival of CD19 CAR-T cells administered to 10 children and young adults with relapsed acute B lymphoblastic leukemia (B-ALL) after UCBT. The study was approved by the Medical Ethics Committee of the First Affiliated Hospital of the University of Sci...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2022-01, Vol.135 (1), p.98-100
Main Authors: Xu, Qianwen, Xu, Hui, Xue, Lei, Wang, Min, Pan, Guiwang, Zhang, Xuhan, Song, Kaidi, Yao, Wen, Wan, Xiang, Tong, Juan, Liu, Huilan, Xu, Hanying, Liu, Xin, Zhu, Xiaoyu, Sun, Zimin, Yang, Lin, Wang, Xingbing
Format: Article
Language:English
Subjects:
Antigens
Antigens, CD19
Bone marrow
Chemotherapy
Cord Blood Stem Cell Transplantation
Correspondence
Disease prevention
Humans
Immunotherapy, Adoptive
Leukemia
Lymphocytes
Mutation
Neurotoxicity
Patients
Polymerase chain reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
Remission (Medicine)
T-Lymphocytes
Transplants & implants
Umbilical cord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here, we report the response rate, toxicity, and survival of CD19 CAR-T cells administered to 10 children and young adults with relapsed acute B lymphoblastic leukemia (B-ALL) after UCBT. The study was approved by the Medical Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China, Hefei, China (No. 2016-101). Proposals to reduce recurrence after CAR-T cell therapy include preventive measures such as novel CARs that target multiple antigens, optimization of CAR design, new manufacturing technologies, or consolidated hematopoietic stem cell transplantation for patients who achieve remission. [...]CD19-targeted CAR-T cell therapy may serve as an alternative for patients with B-ALL who relapse after UCBT.
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000001491